Alkermes plc: Alkermes Presents New Data From Psychiatry Portfolio at 2022 Congress of the Schizophrenia International Research Society
- Detailed Results Presented From ENLIGHTEN-Early Phase 3b Study of LYBALVI in Patients Early in Illness - DUBLIN, April 7, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today presented